Technology News and Research

RSS

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

Scientists use NMR technology to improve protein purification in drug development

The purification of drug components is a large hurdle facing modern drug development. This is particularly true of drugs that utilize proteins, which are notoriously difficult to separate from other potentially deadly impurities. Scientists within the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute are using nuclear magnetic resonance (NMR) to understand and improve an important protein purification process.

30 Sep 2010

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

Mount Sinai School of Medicine received a contract for almost $16.5 million from The National Institutes of Health (NIH) and the National Heart and Lung Institute (NHLBI) through the Program of Excellence in Nanotechnology (PEN). The contract is one of four issued nationally to develop multidisciplinary research Centers with the goal of developing nanotechnology tools for diagnosing and treating heart, lung and blood diseases.

30 Sep 2010

New miRNA screening assay to detect early-stage colorectal cancer

A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity. Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup,said Søren Jensby Nielsen, Ph.D., scientific manager, Diagnostic Product Development, Exiqon A/S

30 Sep 2010

McLean Researchers receive award to create first clinic-ready human induced iPS cells

Belmont, MA-Researchers at Harvard Affiliated McLean Hospital have been awarded a $1.9 million National Institutes of Health Director's Opportunity Award to continue their research into creating human induced pluripotent (iPS) stem cells using a method aimed at eliminating the risk of cancer and other problems associated with other options such as genome-integrating viral methods.

30 Sep 2010

BSD receives patent for heat therapy applicators

BSD Medical Corporation announced today that a patent has been issued to the Company for a new class of heat therapy applicators (antennas). The United States (US) patent office issued the new patent, Transparent electromagnetic applicator and hyperthermia treatment method, to BSD for a unique design for antennas that provides significant benefits for heat therapy applications.

30 Sep 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

Radiologists urge judicious use of radiation-based imaging in children

A CT scan can mean the difference between an accurate and a wrong diagnosis, timely and delayed treatment and, in some cases, life and death. But because CT scans and other tests that use X-ray technology expose the body to often large doses of radiation, their unnecessary, repeated and excessive use may increase cancer risk, especially in children.

30 Sep 2010

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

Researchers develop C5 technology to identify CTCs in breast cancer

Researchers have identified a novel, dual-platform technology, the On-Q-ity Circulating Cancer Capture and Characterization Chip (C5), which they believe is more efficient than the commonly used single-platform device in identifying circulating tumor cells (CTCs) in breast cancer.

30 Sep 2010

Researchers develop genetic screening method to identify drug-resistant HCV strains

In recent human trials for a promising new class of drug designed to target the hepatitis C virus (HCV) without shutting down the immune system, some of the HCV strains being treated exhibited signs of drug resistance.

30 Sep 2010

Midlife crisis is hitting Britons earlier: Survey

The latest British research shows that the tmidlife crisis that was once thought to hit people on their fifties is now affecting people in their mid-thirties. The changes in the work culture may be the main reason say researchers.

30 Sep 2010

ACT updates myoblast program for heart failure treatment

Advanced Cell Technology, a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clinical trials in more than forty patients in over four independent studies.

30 Sep 2010

FDA clears Abbott's RevitaLens Ocutec contact lens disinfecting solution

Abbott has received U.S. Food and Drug Administration (FDA) market clearance for RevitaLens Ocutec™, a unique next-generation multi-purpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.

30 Sep 2010

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

Health IT Blotter: Extension center choices, Medicaid meaningful use, 'build or buy' shift

The U.S. Department of Health and Human Services has selected the final two of 62 regional extension centers (REC), which will help small, rural hospitals and private physicians with the nationwide rollout of electronic medical records (EMR) systems.

30 Sep 2010

UNC scientists receive grant to develop targeted delivery system for pancreatic cancer

A team of UNC scientists has received a five-year $2,308,800 grant from the National Cancer Institute's Cancer Nanotechnology Platform Partnerships to address the critical need for early diagnosis of and more effective treatments for pancreatic cancer.

30 Sep 2010

Starpharma expands partnership with Eli Lilly

Starpharma Holdings Limited (ASX:SPL,OTCQX:SPHRY) today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.

29 Sep 2010

Apricus Biosciences prices securities offering

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that it has entered into agreements with selected investors to sell up to 1,728,882 Units at a price per Unit of $5.40, for aggregate gross proceeds of approximately $9.3 million.

29 Sep 2010

Technology News and Research

AccuPSA test for detecting prostate cancer recurrence

Circassia announces advancement in T-cell allergy vaccines development

Scientists use NMR technology to improve protein purification in drug development

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

New miRNA screening assay to detect early-stage colorectal cancer

McLean Researchers receive award to create first clinic-ready human induced iPS cells

BSD receives patent for heat therapy applicators

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

Radiologists urge judicious use of radiation-based imaging in children

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Researchers develop C5 technology to identify CTCs in breast cancer

Researchers develop genetic screening method to identify drug-resistant HCV strains

Midlife crisis is hitting Britons earlier: Survey

ACT updates myoblast program for heart failure treatment

FDA clears Abbott's RevitaLens Ocutec contact lens disinfecting solution

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Health IT Blotter: Extension center choices, Medicaid meaningful use, 'build or buy' shift

UNC scientists receive grant to develop targeted delivery system for pancreatic cancer

Starpharma expands partnership with Eli Lilly

Apricus Biosciences prices securities offering

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News